CL2021001260A1 - Anticuerpos anti-sirpa humanizados - Google Patents

Anticuerpos anti-sirpa humanizados

Info

Publication number
CL2021001260A1
CL2021001260A1 CL2021001260A CL2021001260A CL2021001260A1 CL 2021001260 A1 CL2021001260 A1 CL 2021001260A1 CL 2021001260 A CL2021001260 A CL 2021001260A CL 2021001260 A CL2021001260 A CL 2021001260A CL 2021001260 A1 CL2021001260 A1 CL 2021001260A1
Authority
CL
Chile
Prior art keywords
humanized anti
sirpa antibodies
treatment
humanized
cancer
Prior art date
Application number
CL2021001260A
Other languages
English (en)
Inventor
Gijsbertus Franciscus Maria Verheijden
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of CL2021001260A1 publication Critical patent/CL2021001260A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con anticuerpos contra SIRPα humanizados adecuados para su uso en el tratamiento contra el cáncer. La invención se relaciona además con el uso de anticuerpos anti-SIRPα humanizados en el tratamiento de tumores sólidos humanos y neoplasias hematológicas, opcionalmente combinados con otros tratamientos contra el cáncer.
CL2021001260A 2018-11-15 2021-05-13 Anticuerpos anti-sirpa humanizados CL2021001260A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18206594 2018-11-15

Publications (1)

Publication Number Publication Date
CL2021001260A1 true CL2021001260A1 (es) 2021-12-24

Family

ID=64331834

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001260A CL2021001260A1 (es) 2018-11-15 2021-05-13 Anticuerpos anti-sirpa humanizados

Country Status (13)

Country Link
US (1) US20210388107A1 (es)
EP (1) EP3880707A1 (es)
JP (1) JP7451520B2 (es)
KR (1) KR20210093270A (es)
CN (1) CN113412279B (es)
AU (1) AU2019378101A1 (es)
BR (1) BR112021009275A2 (es)
CA (1) CA3118966A1 (es)
CL (1) CL2021001260A1 (es)
IL (1) IL282756A (es)
MX (1) MX2021005761A (es)
SG (1) SG11202104431PA (es)
WO (1) WO2020099653A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
US11976119B2 (en) 2018-05-25 2024-05-07 Alector Llc Anti-SIRPa antibodies and methods of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110650976B (zh) * 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
KR20200133376A (ko) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. 신호-조절 단백질 알파에 대한 항체 및 사용 방법
CN114790241A (zh) * 2021-01-26 2022-07-26 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
EP4347653A1 (en) * 2021-06-04 2024-04-10 Boehringer Ingelheim International GmbH Anti-sirp-alpha antibodies
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
JP2014519338A (ja) * 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
CA2896331C (en) * 2012-12-26 2023-08-01 Oncosynergy, Inc. Anti-integrin .beta.1 antibody compositions and methods of use thereof
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
SG11201607143UA (en) * 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
SG11201701189TA (en) * 2014-08-15 2017-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
SG11201808465UA (en) * 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
KR20230142658A (ko) 2016-08-03 2023-10-11 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
SG10201912879YA (en) * 2016-12-09 2020-02-27 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
CN110650976B (zh) * 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
US11976119B2 (en) 2018-05-25 2024-05-07 Alector Llc Anti-SIRPa antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20210388107A1 (en) 2021-12-16
SG11202104431PA (en) 2021-05-28
CN113412279A (zh) 2021-09-17
JP7451520B2 (ja) 2024-03-18
EP3880707A1 (en) 2021-09-22
JP2022509065A (ja) 2022-01-20
CA3118966A1 (en) 2020-05-22
MX2021005761A (es) 2021-08-11
IL282756A (en) 2021-06-30
CN113412279B (zh) 2024-09-24
BR112021009275A2 (pt) 2022-01-04
KR20210093270A (ko) 2021-07-27
WO2020099653A1 (en) 2020-05-22
AU2019378101A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
EA201690080A1 (ru) Применение молекул, ингибирующих семафорин-4d, в комбинации с иммуномодулирующей терапией для ингибирования роста и метастазирования опухолей
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
MX2017001599A (es) Anticuerpos novedosos y sus usos.
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201990978A1 (ru) Антитела против pd-1